RT Journal Article
SR Electronic
T1 High heritability of ascending aortic diameter and multi-ethnic prediction of thoracic aortic disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.29.20102335
DO 10.1101/2020.05.29.20102335
A1 Tcheandjieu, Catherine
A1 Xiao, Ke
A1 Tejeda, Helio
A1 Lynch, Julie A.
A1 Ruotsalainen, Sanni
A1 Bellomo, Tiffany
A1 Palnati, Madhuri
A1 Judy, Renae
A1 Klarin, Derek
A1 Kember, Rachel
A1 Verma, Shefali
A1 Center, Regeneron Genetics
A1 Palotie, Aarno
A1 VA Million Veterans Program, FinnGen Project
A1 Ritchie, Marylyn
A1 Rader, Daniel J.
A1 Rivas, Manuel A.
A1 Assimes, Themistocles
A1 Tsao, Philip
A1 Damrauer, Scott
A1 Priest, James R.
YR 2020
UL http://medrxiv.org/content/early/2020/06/01/2020.05.29.20102335.abstract
AB Enlargement of the aorta is an important risk factor for aortic aneurysm and dissection, a leading cause of morbidity in the developed world. While Mendelian genetics account for a portion of thoracic aortic disease, the contribution of common variation is not known. Using standard techniques in computer vision, we performed automated extraction of Ascending Aortic Diameter (AsAoD) from cardiac MRI of 36,021 individuals from the UK Biobank. A multi-ethnic genome wide association study and trans-ethnic meta-analysis identified 99 lead variants across 71 loci including genes related to cardiovascular development (HAND2, TBX20) and Mendelian forms of thoracic aortic disease (ELN, FBN1). A polygenic risk score predicted prevalent risk of thoracic aortic aneurysm within the UK Biobank (OR 1.50 per standard deviation (SD) polygenic risk score (PRS), p=6.30×10−03) which was validated across three additional biobanks including FinnGen, the Penn Medicine Biobank, and the Million Veterans Program (MVP) in individuals of European descent (OR 1.37 [1.31 - 1.43] per SD PRS), individuals of Hispanic descent (OR 1.40 [1.16 - 1.69] per SD PRS, p=5.6×10−04), and individuals of African American descent (OR 1.08 [1.00 - 1.18] per SD PRS, p=0.05). Within individuals of European descent who carried a diagnosis of thoracic aneurysm, the PRS was specifically predictive of the need for surgical intervention (OR 1.57 [1.15 - 2.15] per SD PRS, p=4.45×10−03). Using Mendelian Randomization our data highlight the primary causal role of blood pressure in reducing dilation of the thoracic aorta. Overall our findings link normal anatomic variation to extremes observed in Mendelian syndromes and provide a roadmap for the use of genetic determinants of human anatomy in both understanding cardiovascular development while simultaneously improving prediction and prevention of human disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNIH R00HL130523 to JRP. Stanford MCHRI Seed Grant to CGT. Funding from the Department of Veterans Affairs Office of Research and Development, Million Veteran Program Grant 1I01BX002641. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and eleven industry partnersAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the use of UKB Imaging and clinical data along with consent from participants was obtained by the National Health Service National Research Ethics Service (ref: 11/NW/0382) and data use approved under applications 15860, 13721, and 24983. The MVP, and Penn Biobank were used as external validation of the association between the PRS of AsAoD and thoracic aortic disease.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data from the UK Biobank are publicly available to qualified researchers at the UK Biobank website https://www.ukbiobank.ac.uk/